Results presented at ESMO show zongertinib produced 79% PFS at 6 months and nearly half of patients remained on treatment at the data cutoff. Investigators reported strong efficacy and tolerability in first-line treatment of advanced HER2-mutant NSCLC.
SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS.
Arielle Kauvar, MD, says pre- and post-treatment care helps prevent hyperpigmentation and complications from laser procedures for all skin types, including skin of color.
Patients beginning their cancer journeys should advocate for themselves and use support groups to help navigate survivorship challenges.
ESMO Congress 2025 in Berlin showcases breakthroughs in precision medicine for bladder, breast, lung, and prostate cancers, enhancing patient quality of life.
ACOs serving patients with complex needs are on the rise, but policy changes are needed to support providers treating special populations.
Payer contracts should incentivize the delivery of comprehensive, total-person cancer care, says Brian Mulherin, MD.
Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.
Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.
Many cancer survivors face ongoing physical and mental health challenges, which peer support and online resources can help address, says Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.
Despite systemic challenges, oncology practices use value-based care, community partnerships, and clinical trials to improve patient access and outcomes, says Brian Mulherin, MD.
Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease.
Some comorbidities associated with psoriatic disease can be treated with GLP-1 RAs and multidisciplinary care.
Eliot F. Battle, MD, a dermatologist, reflects on how he chooses the right treatments for patients with skin of color.
Tiffany Mayo, MD, speaks on emerging therapies for treating hidradenitis suppurativa at the 2025 Skin of Color Update.
Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.
Tiffany Mayo, MD, discusses the emerging therapy landscape for treating patients with hidradenitis suppurativa.
Artificial intelligence, automation, and expanded pharmacist roles help reduce administrative burdens, improve workflow, and support providers in delivering cancer care, according to Scott Soefje, PharmD, MBA, BCOP.
Artificial intelligence (AI) is expanding clinical trial access and enabling drug repurposing, according to Vivek Subbiah, MD.
Empathy and communication strengthen patient-provider relationships and improve respiratory care outcomes, as discussed at the European Respiratory Society (ERS) Congress.
Scott Soefje, PharmD, MBA, BCOP, discusses how remote patient monitoring and caregiver support enable safe outpatient delivery of bispecific antibodies and antibody-drug conjugates.
The European Respiratory Society (ERS) Congress fosters collaboration among global experts, advancing respiratory health and promoting equality in medicine.
FDA approvals since the last Skin of Color Update expand topical and biologic options for various dermatological conditions, benefiting patients with skin of color.
Stronger partnerships between primary care and oncology improve patient outcomes by ensuring coordinated care and addressing financial and systemic barriers, says Mark Fendrick, MD.
Reducing data silos and boosting transparency in oncology requires payer-provider trust and co-governance, according to Vishnukamal Golla, MD, MPH.
Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.
Although overall costs have not declined with the Oncology Care Model (OCM), supportive care costs have decreased through greater use of cost-effective therapies.
Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.
Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.
Oncology pharmacists now work alongside providers to improve efficiency, patient education, and treatment outcomes, according to Scott Soefje, PharmD, MBA, BCOP.
